ASX Life Sciences stocks: Mr. Biotech thinks that 2023 could be a very good year to buy them
Marc Kennis, May 1, 2023
ASX Life Sciences stocks are back, baby!
ASX Life Science stocks have suffered heavily in 2022 due to investors shifting out of risk assets, resulting in a bear market for biotech and medical devices. However, our own Mr. Biotech, Stuart Roberts, believes that now is a good time to buy ASX Life Science stocks, as many high-quality businesses are being overlooked due to poor sentiment.
The bear market has wiped out stocks that were overvalued due to COVID-19 enthusiasm and attracted tourist investors. Stuart sees this as an opportunity to invest in undervalued companies with potential for disruption, although they are currently trading below net asset backing and below cash.
He says stocks to look at include Race Oncology (ASX: RAC), Paradigm Biopharmaceuticals (ASX: PAR), Prescient Therapeutics (ASX: PTX).
Stuart Roberts on AusBiz talking ASX Life Sciences stocks
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
There’s no credit card needed – the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
US Credit Downgrade 2025: Safe Havens or Sell-Offs for Investors?
The US credit downgrade in 2025 has sent ripples through global financial markets, raising serious questions for investors worldwide. When…
What is a REIT’s Funds From Operations (FFO) and how can investors use this metric to their advantage
ASX REITs often use the metric Funds From Operations (FFO). Investors new to investing in REITs may wonder what it…
Microsoft (NDQ:MSFT): There’s still a lot more growth left in this one
Microsoft (NDQ:MSFT) is our International Stock of the Week, but it really needs no introduction. We all use its products…